Cargando…
Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH
Nonalcoholic fatty liver disease (NAFLD) and its evolution to inflammatory steatohepatitis (NASH) are the most common causes of chronic liver damage and transplantation that are reaching epidemic proportions due to the upraising incidence of metabolic syndrome, obesity, and diabetes. Currently, ther...
Autores principales: | Tan, Mingjun, Mosaoa, Rami, Graham, Garrett T., Kasprzyk-Pawelec, Anna, Gadre, Shreyas, Parasido, Erika, Catalina-Rodriguez, Olga, Foley, Patricia, Giaccone, Giuseppe, Cheema, Amrita, Kallakury, Bhaskar, Albanese, Chris, Yi, Chunling, Avantaggiati, Maria Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308387/ https://www.ncbi.nlm.nih.gov/pubmed/31959914 http://dx.doi.org/10.1038/s41418-020-0491-6 |
Ejemplares similares
-
The Mitochondrial Citrate Carrier SLC25A1/CIC and the Fundamental Role of Citrate in Cancer, Inflammation and Beyond
por: Mosaoa, Rami, et al.
Publicado: (2021) -
The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer
por: Fernandez, Harvey R., et al.
Publicado: (2018) -
Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017) -
The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018) -
Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)